Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) - Drugs in Development, 2021

October 2021 | 63 pages | ID: MCF9DCFB1A78EN
Global Markets Direct

Abstracts

Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) - Drugs in Development, 2021

SUMMARY

Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) pipeline Target constitutes close to 14 molecules. Out of which approximately 13 molecules are developed by companies and remaining by the universities/institutes. The latest report Metabotropic Glutamate Receptor 2 - Drugs In Development, 2021, outlays comprehensive information on the Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) - Metabotropic glutamate receptor 2 is a protein encoded by the GRM2 gene. It is a receptor for glutamate. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling inhibits adenylate cyclase activity. May mediate suppression of neurotransmission or may be involved in synaptogenesis or synaptic stabilization. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 2, 6, 4 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Central Nervous System which include indications Schizophrenia, Depression, Major Depressive Disorder, Anxiety Disorders, Drug Addiction, Treatment Resistant Depression, Alzheimer's Disease, Mild Cognitive Impairment, Nicotine Addiction, Panic Disorders, Parkinson's Disease, Partial Seizure, Post-Traumatic Stress Disorder (PTSD), Psychosis, Sleep Disorders and Unspecified Neurologic Disorders.

Furthermore, this report also reviews key players involved in Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The report provides a snapshot of the global therapeutic landscape for Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2)
• The report reviews Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) targeted therapeutics and enlists all their major and minor projects
• The report assesses Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
• The report summarizes all the dormant and discontinued pipeline projects
• The report reviews latest news and deals related to Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) targeted therapeutics

REASONS TO BUY

• Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Identify and understand the targeted therapy areas and indications for Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2)Identify the use of drugs for target identification and drug repurposing
• Identify potential new clients or partners in the target demographic
• Develop strategic initiatives by understanding the focus areas of leading companies
• Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
• Devise corrective measures for pipeline projects by understanding Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) development landscape
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction
Global Markets Direct Report Coverage
Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) - Overview
Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) - Companies Involved in Therapeutics Development
Addex Therapeutics Ltd
Bristol-Myers Squibb Co
Camino Pharma LLC
Denovo Biopharma LLC
Eli Lilly and Co
Gate Neurosciences Inc
Johnson & Johnson
Merck & Co Inc
Noema Pharma AG
Taisho Pharmaceutical Holdings Co Ltd
Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) - Drug Profiles
BMT-133218 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GATE-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JNJ-40411813 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JNJ-5515 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LY-3020371 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NOE-109 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pomaglumetad methionil - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SBP-0069330 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SBP-9881 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Agonize Metabotropic Glutamate Receptor 2 for Psychosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize mGlu2 for Anxiety and Depression - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize MGLUR2 for Cardiovascular and Central Nervous System Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TS-134 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TS-161 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) - Dormant Products
Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) - Discontinued Products
Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) - Product Development Milestones
Featured News & Press Releases
Aug 25, 2021: Camino Pharma initiates phase 1 study of SBP-9330 in development for the treatment of tobacco use disorder
Jul 01, 2021: Addex, Stanford University and University of Copenhagen Publish mGlu2 Structure in Nature Using Addex Allosteric Modulators
Jun 07, 2021: Addex starts phase 2 clinical study of ADX71149 for epilepsy
Jan 21, 2021: Addex ADX71149 receives IND approval to start a phase 2a clinical study in epilepsy
Sep 16, 2020: $11.4 million NIH grant advances drug to treat nicotine addiction
Jun 30, 2020: Camino Pharma receives $920K Small Business Innovation Research (SBIR) grant from the National Institute of Mental Health
Jun 16, 2020: Addex mGlu2 PAM program to advance into Epilepsy Phase 2a proof of concept clinical study
Oct 02, 2018: Addex selective mGlu2 PAM ADX71149 included in review highlighting promising investigative drugs for epilepsy
Sep 04, 2018: Addex’s selective mGlu2 PAM ADX71149 shows promise in treating severe panic disorders and PTSD
Feb 27, 2017: Addex's ADX71149 Anti-Epileptic Effect Highlighted in Scientific Journal, Epilepsia
Sep 23, 2015: Addex ADX71149 Demonstrates Synergistic Efficacy with Levetiracetam in Preclinical Models of Epilepsy
Feb 07, 2014: Addex Reports Top-line Data from ADX71149 Phase 2a Study in Patients with Major Depressive Disorder with Significant Anxiety Symptoms
Oct 29, 2013: Addex Licensee Completes Enrolment of 120 Patients in a Phase 2 Clinical Trial of ADX71149 for the Treatment of Anxious Depression
Nov 05, 2012: Addex Reports Top-line Data From Successful Phase IIa Clinical Study With ADX71149 In Schizophrenia Patients
Nov 05, 2012: Addex Therapeutics Reports Top-line Data From Phase IIa Clinical Study With ADX71149 In Schizophrenia Patients
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Indication, 2021
Number of Products under Development by Companies, 2021
Products under Development by Companies, 2021
Products under Development by Companies, 2021 (Contd..1)
Number of Products under Investigation by Universities/Institutes, 2021
Products under Investigation by Universities/Institutes, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Pipeline by Addex Therapeutics Ltd, 2021
Pipeline by Bristol-Myers Squibb Co, 2021
Pipeline by Camino Pharma LLC, 2021
Pipeline by Denovo Biopharma LLC, 2021
Pipeline by Eli Lilly and Co, 2021
Pipeline by Gate Neurosciences Inc, 2021
Pipeline by Johnson & Johnson, 2021
Pipeline by Merck & Co Inc, 2021
Pipeline by Noema Pharma AG, 2021
Pipeline by Taisho Pharmaceutical Holdings Co Ltd, 2021
Dormant Products, 2021
Dormant Products, 2021 (Contd..1)
Dormant Products, 2021 (Contd..2)
Discontinued Products, 2021

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Top 10 Indications, 2021
Number of Products by Mechanism of Actions, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Stage and Molecule Type, 2021